Prolia (Denosumab) Cost in Alaska 2026

What Does Prolia (Denosumab) Actually Cost in Alaska?

The cash price for a single Prolia injection at Alaska retail pharmacies runs close to $1 to 500 in 2026, which matches Amgen's published wholesale acquisition cost for the 60 mg/mL prefilled syringe. Because the drug is given every six months, out-of-pocket annual exposure without any assistance can reach $3,000 or more once dispensing fees are added.

That number sounds stark, but it rarely reflects what most patients pay. Medicare Part B, commercial health insurance, manufacturer assistance programs, and compounded denosumab through a state-licensed 503A pharmacy each offer a different ceiling on real-world cost. The right path depends on your payer status, income, and risk tolerance around compounded products.

Prolia received FDA approval in 2010 for postmenopausal osteoporosis and has since earned additional indications covering bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and giant cell tumor of bone [1]. Its mechanism differs completely from bisphosphonates: denosumab is a fully human monoclonal antibody that binds RANK ligand, blocking osteoclast formation, function, and survival [2].

The key FREEDOM trial (N=7,808, postmenopausal women with a T-score between -2.5 and -4.0) demonstrated that subcutaneous denosumab 60 mg every six months over 36 months reduced the relative risk of new vertebral fracture by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001), hip fracture by 40%, and nonvertebral fracture by 20% compared with placebo [3]. Those fracture-reduction numbers drive the clinical rationale for its cost.

How Alaska Medicaid Handles Prolia Coverage

Alaska Medicaid does not cover Prolia for osteoporosis as of 2026. Patients enrolled in the Alaska Medicaid fee-for-service program who need denosumab for a non-cancer bone-loss indication will need to pay cash, seek manufacturer assistance, or discuss alternative agents with their prescriber.

The exclusion is not unusual at the national level. Medicaid preferred drug lists in several states restrict or exclude branded biologics in favor of bisphosphonates such as alendronate, which cost less than $10 per month in generic form. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines do position denosumab as a first-line option for patients with high or very high fracture risk, including those with a T-score at or below -2.5 plus prior fragility fracture [4]. That clinical standing, however, does not automatically translate to Medicaid formulary placement in Alaska.

Patients on Alaska Medicaid who have a documented bisphosphonate contraindication or intolerance may attempt a formulary exception or prior authorization appeal. A prescriber letter citing the specific contraindication and referencing the AACE guidelines can support such a request, but approval is not guaranteed. An endocrinologist or certified bone health specialist at a facility such as Alaska Native Tribal Health Consortium or Providence Alaska Medical Center can assist with the documentation.

Alaska Medicaid Coverage Decision Framework for Denosumab

1. Confirm the clinical indication (postmenopausal osteoporosis, cancer-related bone loss, or giant cell tumor).
2. Check whether the indication falls under medical benefit (Part B equivalent, provider-administered) vs. pharmacy benefit. Cancer indications administered in a clinic may route through the medical benefit and face different formulary rules.
3. If denied, obtain a written denial and file a prior authorization appeal with bisphosphonate contraindication documentation.
4. If appeal fails, pivot to Amgen patient assistance or 503A compounding (see sections below).

Medicare Part B and Part D Coverage in Alaska

Medicare coverage of Prolia splits by how the drug is administered. When a provider administers the injection in a clinic or infusion suite, it bills under Medicare Part B as a covered injectable biologic. The patient typically pays 20% of the Medicare-approved amount after the Part B deductible, which comes to roughly $200 to $300 per injection for a patient without a Medigap supplement.

When a patient self-injects at home using a pharmacy-dispensed prefilled syringe, the drug falls under Medicare Part D (the prescription drug benefit). Part D coverage depends on the specific plan formulary. Most Part D plans that carry Prolia place it on a specialty tier, where cost-sharing can reach 25% to 33% of the drug cost even after deductible. For a $1,500 injection, that means $375 to $500 per dose before the out-of-pocket cap kicks in.

The Medicare Part D out-of-pocket cap, established by the Inflation Reduction Act and phased in through 2025, limits true out-of-pocket drug spending to $2,000 per year starting in 2025 [5]. For Alaskans on Part D who need two Prolia injections annually, this cap offers meaningful protection once the threshold is crossed.

Patients should use the Medicare Plan Finder at medicare.gov each fall during open enrollment to compare Part D plans by Prolia tier placement and cost-sharing structure, since formularies change annually.

Commercial Insurance Coverage in Alaska

Most commercial health plans operating in Alaska, including Premera Blue Cross, Moda Health, and plans on the Alaska Health Insurance Exchange, cover Prolia for FDA-approved indications subject to prior authorization. The standard criteria mirror those used nationally: a confirmed osteoporosis diagnosis (T-score at or below -2.5, or prior fragility fracture), and often a documented trial or contraindication to a first-line bisphosphonate.

After prior authorization approval, cost-sharing depends on the specific plan design. High-deductible health plans common among Alaskans in the individual market may require the full specialty-tier cost to apply toward the deductible before any plan payment begins. A patient with a $4,000 deductible receiving two injections per year could owe $3,000 before the plan pays anything, assuming the negotiated rate aligns with the list price.

The practical step: call the member services number on your insurance card and ask specifically whether Prolia is on the formulary, what tier it sits on, what prior authorization criteria apply, and whether a specialty pharmacy is required. Some plans mandate dispensing through a specific specialty pharmacy rather than a local Alaska retail chain.

The Amgen Prolia Savings Card: How It Works for Alaskans

Amgen operates a commercial co-pay savings program for Prolia that can reduce out-of-pocket cost to $0 per dose for eligible commercially insured patients. The card is not available to patients whose primary insurance is a federal program, meaning Medicare, Medicaid, or any other government-funded plan.

Eligibility requirements as of 2026 include:

• Commercial (private) insurance that covers Prolia.
• U.S. residency, which includes Alaska.
• Not enrolled in Medicare Part A or B, Medicaid, or any state or federally funded prescription assistance program.

Patients who qualify can enroll online at amgen.com or by calling Amgen SupportPlus. The card is presented at the pharmacy or to the administering provider at each visit. Amgen pays the co-pay difference up to the program maximum, which has historically been set high enough to cover most commercial plan cost-sharing structures.

For uninsured patients or those who do not qualify for the co-pay card, Amgen also runs the Amgen Safety Net Foundation, a patient assistance program that provides Prolia free of charge to patients meeting income-based criteria. Household income at or below 500% of the federal poverty level may qualify. Applications require prescriber documentation and proof of income.

"Amgen's patient support programs are designed to help ensure that patients who are prescribed Prolia can access their medication regardless of their insurance status or financial situation," according to program materials published by Amgen SupportPlus.

Compounded Denosumab in Alaska: Legality and Practical Access

Compounded denosumab is legally available in Alaska through state-licensed 503A compounding pharmacies. A 503A pharmacy operates under the federal Drug Quality and Security Act and state pharmacy board oversight; it may prepare patient-specific compounded formulations when a licensed prescriber writes a valid prescription [6].

The cost differential is striking. Commercially available Prolia costs roughly $1,500 per injection. A compounded denosumab formulation from a 503A pharmacy may cost substantially less, and some HealthRX-partnered pharmacies offer it to qualifying patients at significantly reduced rates.

Three points deserve careful attention before a patient pursues this route.

First, the FDA has not approved any compounded denosumab product. Approved Prolia and Xgeva (the higher-dose oncology formulation) underwent rigorous clinical testing; a compounded preparation has not gone through the same regulatory review process. The monoclonal antibody structure of denosumab is far more complex to reproduce than a small-molecule drug, and potency, sterility, and stability of a compounded product depend entirely on the specific pharmacy's quality systems.

Second, the AACE osteoporosis guidelines and the American Society for Bone and Mineral Research position statements do not endorse compounded denosumab as a substitute for the approved product. Prescribers carrying out clinical practice within those guidelines should document the clinical rationale when prescribing compounded versions.

Third, abrupt discontinuation of denosumab carries a well-documented rebound risk. A 2017 paper in Osteoporosis International reported that stopping denosumab without transitioning to an antiresorptive agent leads to rapid bone mineral density loss and a spike in vertebral fracture risk within 12 to 24 months [7]. That rebound applies to any denosumab, compounded or branded. Patients and prescribers must plan the full treatment duration and any transition strategy before starting the drug, regardless of which version is used.

For patients who choose the compounded route, the Alaska State Board of Pharmacy maintains a list of licensed in-state pharmacies. Out-of-state 503A pharmacies may ship to Alaska patients if licensed in the originating state, but the patient and prescriber bear responsibility for verifying that licensing.

Telehealth Prescribing of Prolia in Alaska

Prolia may be prescribed via telehealth in Alaska. The state's telehealth statutes do not carve out an exclusion for injectable biologics, and the post-pandemic expansion of telehealth prescribing authority for non-controlled substances remained in place through 2025 legislative sessions.

A telehealth-based prescribing visit at HealthRX or a similar platform allows an Alaskan patient to have a bone health assessment and DEXA review without traveling to Anchorage, Fairbanks, or Juneau. The prescriber evaluates fracture risk using the FRAX tool, reviews prior DEXA T-scores, screens for contraindications (hypocalcemia must be corrected before the first dose, per the FDA label), and sends the prescription electronically to the patient's preferred pharmacy or directly to an administering provider.

The injection itself still requires a clinical setting or a trained self-injector. Many rural Alaskan patients receiving care through Indian Health Service facilities or community health aides can arrange for injection administration at their local clinic after receiving a telehealth prescription. Coordination between the telehealth prescriber and the local administering provider is standard practice and does not require the patient to leave their community.

Comparing Denosumab to Lower-Cost Osteoporosis Alternatives

Before spending $1,500 per injection, it is worth confirming that denosumab is the appropriate choice for a given patient rather than a less expensive alternative.

Generic alendronate (Fosamax), the most prescribed bisphosphonate, costs $8 to $15 per month at most Alaska pharmacies. The FLEX trial showed that five years of alendronate followed by a drug holiday maintained vertebral fracture protection in many patients [8]. For a patient with a T-score near -2.5 and no prior fracture, alendronate may provide comparable fracture reduction at a fraction of the price.

Denosumab holds specific advantages in several scenarios. Patients with chronic kidney disease stages 3b to 4 may not tolerate bisphosphonates and denosumab does not accumulate in bone or require renal dose adjustment at those stages, per the FDA label. Patients who cannot reliably adhere to weekly oral dosing benefit from the twice-yearly injection schedule. Women with a history of esophageal disorders may prefer to avoid oral bisphosphonates entirely.

Zoledronic acid (Reclast), an intravenous bisphosphonate given once yearly, falls between alendronate and denosumab in both cost and convenience. The HORIZON trial (N=7,765) showed a 70% relative risk reduction in morphometric vertebral fracture over three years versus placebo (P<0.001) [9]. Generic zoledronic acid infusions can run $150 to $400 at Alaska infusion centers, making this a cost-competitive alternative for patients who need an injectable option.

What Alaskans Should Do Before Their Next Injection

The practical sequence for a new or existing Prolia patient in Alaska who wants to minimize cost without compromising care:

Check insurance first. Call your plan, confirm the formulary tier, and ask for the prior authorization criteria in writing.

If commercially insured, enroll in the Amgen savings card immediately. Processing takes minutes online and can reduce cost-sharing to $0 at the next injection visit.

If on Medicare Part B and receiving the injection in a provider's office, the 20% coinsurance is typically lower than Part D specialty-tier cost-sharing. Ask your provider whether in-office administration is available.

If on Alaska Medicaid, request a prior authorization appeal if bisphosphonates are contraindicated. Simultaneously explore the Amgen Safety Net Foundation application.

If uninsured or underinsured and considering compounded denosumab, discuss the clinical tradeoffs with your prescriber. Confirm the 503A pharmacy's licensing, request a certificate of analysis for each batch, and plan your transition strategy for when you eventually stop treatment.

Do not stop denosumab without a plan. The rebound vertebral fracture risk documented in the literature is real and can be severe; a 2019 case series in the Journal of Bone and Mineral Research described multiple vertebral fractures occurring within 8 months of denosumab discontinuation in patients who did not receive bridging therapy [10].

Patients with a FRAX 10-year major osteoporotic fracture probability at or above 20%, or a hip fracture probability at or above 3%, meet the National Osteoporosis Foundation threshold for pharmacologic treatment [11]. At those risk levels, continuity of therapy matters as much as initial choice.

A telehealth consultation through HealthRX can confirm your current DEXA results, recalculate your FRAX score, and establish a cost-aware treatment plan that accounts for your specific Alaskan payer situation.